Dysphagia· 2026Q1
Nicergoline for Neuromuscular Oropharyngeal Dysphagia: A Double-Blind, Placebo-Controlled Randomized Trial
- 0citations
- Q1SCImago
- 2026year
Short summary
Nicergoline (30 mg daily for 4 weeks) significantly improved airway protection during swallowing in patients with neuromuscular oropharyngeal dysphagia, as evidenced by a reduction in the penetration-aspiration scale score, although it did not significantly alter overall swallow function scores.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openSpeech and HearingHealth Professions